Literature DB >> 33679779

Adjunct Therapy for CD4+ T-Cell Recovery, Inflammation and Immune Activation in People Living With HIV: A Systematic Review and Meta-Analysis.

Yang Zhang1,2,3, Taiyi Jiang1, Aixin Li1, Zhen Li1,2, Jianhua Hou1,2, Meixia Gao1, Xiaojie Huang1, Bin Su1,2, Hao Wu1,2, Tong Zhang1,2, Wei Jiang3,4.   

Abstract

Background: HIV infection results in immune homeostasis perturbations, which is characterized by CD4+ T-cell depletion, immune activation, and inflammation. Effective antiretroviral therapy (ART) does not fully restore immunologic and clinical health in people living with HIV (PLWH). Various drugs have been used to improve their immune status and CD4+ T-cell counts, but no measures have been tested effective. Here we conduct a systematic review and meta-analysis of existing clinical studies on improving CD4+ T-cell count while decreasing inflammation and immune activation.
Methods: We retrieved possible relevant publications from a total of five electronic databases and selected eligible studies, which dealt with outcomes of medical therapy for CD4+ T-cell count recovery, inflammation, and immune activation with or without ART. We paid particular attention to immunologic non-responders with a favorable treatment regimen.
Results: Thirty-three articles were included in the systematic review and meta-analysis. However, there were no safe and effective medications specific for improving CD4+ T-cell reconstitution. The immunological benefits or adverse events mainly depend on the safety, dosage, and duration of the candidate medication use, as well as whether it is combined with ART.
Conclusion: Under the "safe, combined, adequate and long (SCAL)" principles, alternative approaches are needed to accelerate the recovery of CD4+ T-cells, and to prevent adverse long-term outcomes in PLWH with standard ART treatment.
Copyright © 2021 Zhang, Jiang, Li, Li, Hou, Gao, Huang, Su, Wu, Zhang and Jiang.

Entities:  

Keywords:  CD4+ T-cell; adjunct therapy; immune activation; immunologic non-responder; inflammation; people living with HIV

Year:  2021        PMID: 33679779      PMCID: PMC7925844          DOI: 10.3389/fimmu.2021.632119

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  47 in total

1.  Placebo-controlled trial of prednisone in advanced HIV-1 infection.

Authors:  G A McComsey; C C Whalen; S D Mawhorter; R Asaad; H Valdez; A H Patki; J Klaumunzner; K V Gopalakrishna; L H Calabrese; M M Lederman
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Four Decades of HIV/AIDS - Much Accomplished, Much to Do.

Authors:  Anthony S Fauci; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-07-02       Impact factor: 91.245

3.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Authors:  Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  Lancet       Date:  2014-07-19       Impact factor: 79.321

4.  Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138.

Authors:  Michael M Lederman; Laura Smeaton; Kim Y Smith; Benigno Rodriguez; Minya Pu; Hongying Wang; Anne Sevin; Pablo Tebas; Scott F Sieg; Kathy Medvik; David M Margolis; Richard Pollard; Hildegund C J Ertl; Hernan Valdez
Journal:  J Infect Dis       Date:  2006-11-02       Impact factor: 5.226

5.  Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

Authors:  Nicholas T Funderburg; Ying Jiang; Sara M Debanne; Danielle Labbato; Steven Juchnowski; Brian Ferrari; Brian Clagett; Janet Robinson; Michael M Lederman; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

6.  A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.

Authors:  Tae Joon Yi; Sharon Walmsley; Leah Szadkowski; Janet Raboud; Nimerta Rajwans; Brett Shannon; Sachin Kumar; Kevin C Kain; Rupert Kaul; Darrell H S Tan
Journal:  Clin Infect Dis       Date:  2013-08-14       Impact factor: 9.079

7.  Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

Authors:  Nicholas I Paton; Ruth L Goodall; David T Dunn; Samuel Franzen; Yolanda Collaco-Moraes; Brian G Gazzard; Ian G Williams; Martin J Fisher; Alan Winston; Julie Fox; Chloe Orkin; Elbushra A Herieka; Jonathan G Ainsworth; Frank A Post; Mark Wansbrough-Jones; Peter Kelleher
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

8.  A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.

Authors:  Meagan P O'Brien; Peter W Hunt; Douglas W Kitch; Karin Klingman; James H Stein; Nicholas T Funderburg; Jeffrey S Berger; Pablo Tebas; Brian Clagett; Daniela Moisi; Netanya S Utay; Fran Aweeka; Judith A Aberg
Journal:  Open Forum Infect Dis       Date:  2017-01-19       Impact factor: 3.835

9.  Vitamin D and Phenylbutyrate Supplementation Does Not Modulate Gut Derived Immune Activation in HIV-1.

Authors:  Catharina Missailidis; Nikolaj Sørensen; Senait Ashenafi; Wondwossen Amogne; Endale Kassa; Amsalu Bekele; Meron Getachew; Nebiat Gebreselassie; Abraham Aseffa; Getachew Aderaye; Jan Andersson; Susanna Brighenti; Peter Bergman
Journal:  Nutrients       Date:  2019-07-21       Impact factor: 5.717

10.  Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation.

Authors:  Priscilla Y Hsue; Rebecca Scherzer; Peter W Hunt; Amanda Schnell; Ann F Bolger; S C Kalapus; Kristinalisa Maka; Jeffrey N Martin; Peter Ganz; Steven G Deeks
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  3 in total

1.  Plasma MicroRNA Signature Panel Predicts the Immune Response After Antiretroviral Therapy in HIV-Infected Patients.

Authors:  Jun-Nan Lv; Jia-Qi Li; Ying-Bin Cui; Yuan-Yuan Ren; Ya-Jing Fu; Yong-Jun Jiang; Hong Shang; Zi-Ning Zhang
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

2.  Decreased CD73+ Double-Negative T Cells and Elevated Level of Soluble CD73 Correlated With and Predicted Poor Immune Reconstitution in HIV-Infected Patients After Antiretroviral Therapy.

Authors:  Xinyue Wang; Leidan Zhang; Juan Du; Yuqing Wei; Di Wang; Chuan Song; Danying Chen; Bei Li; Meiqing Jiang; Mengyuan Zhang; Hongxin Zhao; Yaxian Kong
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

3.  Elevated Foxp3+ double-negative T cells are associated with disease progression during HIV infection.

Authors:  Leidan Zhang; Yuqing Wei; Di Wang; Juan Du; Xinyue Wang; Bei Li; Meiqing Jiang; Mengyuan Zhang; Na Chen; Meiju Deng; Chuan Song; Danying Chen; Liang Wu; Jiang Xiao; Hongyuan Liang; Hongxin Zhao; Yaxian Kong
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.